The Nurse Practitioner. 47(10):27-36, October 2022.

Selecting noninvasive diagnostic tests for coronary artery disease can be a daunting task to acute care NPs. This article provides an overview of the pathophysiology of coronary artery disease, relevant noninvasive diagnostic imaging modalities, and an evidence-based approach to guide subsequent diagnostic and therapeutic interventions.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Free
• CE Test

The Nurse Practitioner. 47(6):30-37, June 2022.

Hypertension affects almost 20% of Canada's population and is even more prevalent in rural locations due to decreased availability of healthcare; lower income levels and levels of formal education; and higher rates of obesity, smoking, and alcohol use, among others. This article uses current evidence to describe the management of primary hypertension in rural populations.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Buy

The Nurse Practitioner. 47(6):5-9, June 2022.

• Favorite
• PDF
• Permissions

• Buy

The Nurse Practitioner. 47(5):32-38, May 2022.

The Physician Fee Schedule was updated in 2021 by the Centers for Medicare and Medicaid Services. A case study on Tetralogy of Fallot, the most common cyanotic congenital heart defect, is presented with guidance in billing the office visit to reflect the current guidelines.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Buy

The Nurse Practitioner. 47(3):40-47, March 2022.

The prevalence of hypertension in Black women (57.6%) is among the highest in the world. Many of those who identify as Black do not readily adhere to prescribed antihypertensive medications nor persist with long-term therapy. This qualitative study describes self-reported approaches used by Black women with consistent adherence and persistence to medication-taking for BP control.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Buy

The Nurse Practitioner. 47(2):40-46, February 2022.

The American Heart Association scientific statement on cardiogenic shock and the National Cardiogenic Shock Initiative have provided the impetus to advance knowledge and development of national guidelines for cardiogenic shock. We evaluate the current state of knowledge surrounding cardiogenic shock and limitations to the development of national guidelines.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Buy

The Nurse Practitioner. 46(11):50-55, November 2021.

Since 2020, several guidelines have been published to help health practitioners better manage hypertension and diabetes in patients with chronic kidney disease. Scrutiny on the inclusion of race in determining the estimated glomerular filtration rate (eGFR) as well as breakthrough research regarding the drug dapagliflozin for the treatment of patients with chronic kidney disease are discussed.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Buy

The Nurse Practitioner. 46(10):50-55, October 2021.

Patients who present to an outpatient office with hypertensive urgency—or severely elevated BP without evidence of acute target organ damage—can be safely treated in the ambulatory setting by initiating or reestablishing long-acting oral antihypertensive medications, addressing medication nonadherence, and reviewing precipitating factors.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Free

The Nurse Practitioner. 46(9):14-22, September 2021.

Patients with aortic stenosis are at risk for developing hypertension. This article provides an overview of antihypertensives used in patients with aortic stenosis, focusing on renin-angiotensin system inhibitors, beta-blockers, diuretics, and vasodilators.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Free
• CE Test

The Nurse Practitioner. 46(7):30-37, July 2021.

Sodium-glucose cotransporter-2 (SGLT2) inhibitors can decrease risk for heart failure in patients with type 2 diabetes and can decrease risk of major cardiovascular events in patients with heart failure (HF) and diabetes. Specific SGLT2 inhibitors can also decrease major cardiovascular events in patients with HF only.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Free
• CE Test

The Nurse Practitioner. 46(7):10-13, July 2021.

• Favorite
• PDF
• Permissions

• Buy

The Nurse Practitioner. 46(6):26-27, June 2021.

• Favorite
• PDF
• Permissions

• Buy

The Nurse Practitioner. 46(3):46-50, March 2021.

Heart failure readmission rates continue to rise and cause economic burden in the US. Advancements in hemodynamic monitoring offer the ability to monitor intracardiac pressures at home and provide data that are used to optimize outpatient management of heart failure, resulting in reduced hospitalization and mortality associated with heart failure.

• Abstract
  Abstract
• In Brief
  In Brief
• Favorite
• PDF
• Permissions

• Buy